How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent
Description:
This study aims to establish the recommended dose of [177Lu]Lu-DOTA-TATE in combination with the standard of care or as single agent in three different groups of participants with Glioblastoma (a brain cancer).
Sponsor:
NovartisGovernment Study Link:
NCT05109728 - Click here to see study onClinicalTrials.gov
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States 🇺🇸
University of Wisconsin
Madison, Wisconsin 53792, United States
Principal Investigator
Ankus Bhatia, MD
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
Principal Investigator
Jan Drappatz, MD
M D Anderson Cancer Center
Houston, Texas 77030, United States
Principal Investigator
Nazanin K. Majd, MD
